Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS predicts fewer Xigris patients

Executive Summary

Centers for Medicare and Medicaid Services is revising downward estimates for add-on payments for Lilly's Xigris (drotrecogin alfa). Agency estimates 14,000 Medicare patients will be administered therapy in fiscal 2004 compared to 22,000-patient estimate for FY 2003. CMS' original 2003 payment estimate assumed 50,000 Medicare patients (1"The Pink Sheet" Aug. 5, 2002, p. 18) Xigris sales have not matched Lilly's expectations (2"The Pink Sheet" Nov. 18, 2002, p. 22)...

You may also be interested in...



Lilly Xigris Marketing Plans Stress Journal Articles, “Sharpened” Messages

Lilly is planning to publish a series of peer-reviewed Xigris journal articles as part of a continued effort to build market acceptance of the sepsis agent

Xigris Medicare “Add-On” Payments Approved; CMS Estimates 50,000 Cases

The Centers for Medicare & Medicaid Services is estimating that the Medicare market for Lilly's Xigris will be $340 mil. in fiscal year 2003

Neuroscience Challenges Oncology For Top Spot In CDER’s 2019 Novel Approvals

Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.

UsernamePublicRestriction

Register

PS041807

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel